BioCryst Pharmaceuticals (BCRX) Surpasses Q2 Earnings and Revenue Estimates

Group 1 - BioCryst Pharmaceuticals reported quarterly earnings of $0.15 per share, exceeding the Zacks Consensus Estimate of $0.03 per share, compared to a loss of $0.06 per share a year ago, representing an earnings surprise of +400.00% [1] - The company posted revenues of $163.35 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 9.74%, and compared to year-ago revenues of $109.33 million [2] - BioCryst has surpassed consensus EPS estimates two times over the last four quarters and topped consensus revenue estimates four times during the same period [2] Group 2 - The stock's immediate price movement will depend on management's commentary during the earnings call, with BioCryst shares gaining about 5.7% since the beginning of the year, compared to the S&P 500's gain of 6.1% [3] - The current consensus EPS estimate for the coming quarter is $0.06 on revenues of $155.49 million, and $0.13 on revenues of $609.2 million for the current fiscal year [7] - The Zacks Industry Rank for Medical - Drugs is currently in the top 32% of over 250 Zacks industries, indicating that the industry outlook can significantly impact stock performance [8]